about
Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study.Lipoprotein particle subclasses, cardiovascular disease and HIV infection.Highly active antiretroviral therapy and coronary heart disease: the need for perspective.Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.Predictors of hypertension and changes of blood pressure in HIV-infected patients.Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study.Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionPrevention Strategies for Cardiovascular Disease in HIV-Infected PatientsResponse to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA studyCan the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools?[Carbon monoxide poisoning]
P50
Q30762470-D46EF54E-3F11-444F-AAE5-5ED23AD0D94FQ33639078-7D35B98E-BDCB-431A-92E1-AD43B2637D3FQ34509257-05B7269F-AA49-4F4B-A730-50259C281624Q35051199-1AE32E7A-7ABC-4170-B963-8E3439B46903Q35873877-E7B10F80-9E8B-4C5F-A13F-7C7CD294BB32Q37242966-37F0E1FD-9BA1-43E2-AF27-42D5F34BD931Q38596011-5FDBD741-463B-4B0F-8D53-E02CBA564C7CQ43253410-CE00D707-AE31-43EF-AA9A-493B5376ECC6Q44055963-2D3F7CD6-95CA-486D-B9D9-A79E89D82DD9Q46589510-3E0D2CC6-6288-47A9-A759-E66FE21495EBQ46825807-7779B260-58F7-4AF2-956E-51928EAEC29CQ51984203-C4AD7609-AB9B-4006-ADED-B976C2B06FFAQ57181081-12D40378-49FA-426E-AF91-E23E138D0E53Q58375403-F738D6D9-7F39-47A7-BD7B-33EE9641D589Q74090088-096ED9EF-0A8B-4AD8-9517-5135DE0A0515Q81321073-8C67C478-018F-450B-AD3C-AFFF10CE2305Q83772218-EE9C1689-6E82-442D-B810-DD266E1314FD
P50
description
researcher, ORCID id # 0000-0002-7449-7393
@en
wetenschapper
@nl
name
Nina Friis-Moller
@ast
Nina Friis-Moller
@en
Nina Friis-Moller
@es
Nina Friis-Moller
@nl
type
label
Nina Friis-Moller
@ast
Nina Friis-Moller
@en
Nina Friis-Moller
@es
Nina Friis-Moller
@nl
prefLabel
Nina Friis-Moller
@ast
Nina Friis-Moller
@en
Nina Friis-Moller
@es
Nina Friis-Moller
@nl
P106
P31
P496
0000-0002-7449-7393